Technical Analysis for TRVI - Trevi Therapeutics, Inc.

Grade Last Price % Change Price Change
D 3.01 2.21% 0.07
TRVI closed up 2.21 percent on Friday, November 1, 2024, on 88 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 6
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction 2.21%
NR7 Range Contraction 2.21%
Stochastic Reached Oversold Weakness 2.21%
Down 3 Days in a Row Weakness 2.21%
Oversold Stochastic Weakness 2.21%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 21 hours ago
Outside Day about 21 hours ago
Fell Below Lower Bollinger Band about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
Down 2 % about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Trevi Therapeutics, Inc. Description

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Organic Compounds Chemical Compounds Opioids Analgesics Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Ethers Nervous System Morphinans Physiology Cough Phenols Parkinson’s Disease Opioid Receptors Pruritus Dyskinesia Peripheral Nervous System Prurigo Prurigo Nodularis

Is TRVI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.0
52 Week Low 0.9712
Average Volume 414,873
200-Day Moving Average 2.80
50-Day Moving Average 3.15
20-Day Moving Average 3.11
10-Day Moving Average 3.13
Average True Range 0.20
RSI (14) 45.05
ADX 10.43
+DI 18.27
-DI 22.93
Chandelier Exit (Long, 3 ATRs) 2.84
Chandelier Exit (Short, 3 ATRs) 3.37
Upper Bollinger Bands 3.32
Lower Bollinger Band 2.90
Percent B (%b) 0.26
BandWidth 13.69
MACD Line -0.03
MACD Signal Line 0.00
MACD Histogram -0.0217
Fundamentals Value
Market Cap 192.21 Million
Num Shares 63.9 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -13.68
Price-to-Sales 0.00
Price-to-Book 1.17
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.27
Resistance 3 (R3) 3.26 3.15 3.23
Resistance 2 (R2) 3.15 3.09 3.16 3.21
Resistance 1 (R1) 3.08 3.05 3.12 3.10 3.20
Pivot Point 2.98 2.98 3.00 2.99 2.98
Support 1 (S1) 2.91 2.91 2.94 2.92 2.82
Support 2 (S2) 2.80 2.87 2.81 2.81
Support 3 (S3) 2.73 2.80 2.79
Support 4 (S4) 2.75